MedPath

Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome

Not Applicable
Recruiting
Conditions
Down Syndrome
Interventions
Other: Biological sampling
Registration Number
NCT05767216
Lead Sponsor
Institut Jerome Lejeune
Brief Summary

Heterokaryotypic monozygotic twins discordant for Down syndrome (DS) are very rare, with an incidence estimated to be less than 1 over 7,000,000 pregnancy in the general population. Sharing the same genetic patrimony, except for an additional chromosome 21 for one of them, any gene-expression difference between them could be attributed only to the supernumerary chromosome 21 and not to polymorphic variability in the rest of the genome. The setting up of a prospective longitudinal study will offer the major advantage of allowing genetic and epigenetic comparisons between them and to obtain important information on the impact of the environment in which they live and grow up.

Detailed Description

It is planned to perform multi-omics analyses in order to reach an integrated understanding of the effect of genomic changes on protein expression, on biochemical posttranslational modifications of the synthetized proteins and on the modulation of some signalling pathways.

This study will also allow the generation of induced Pluripotent Stem Cells (iPSCs) from blood cells and fibroblasts of the monozygotic twins useful as in-vitro models to study the pathogenesis and the pathophysiology of Down syndrome. All this may shed the light on new research approaches in Down syndrome.

At last, the human gut microbiome, referring to the total microbial population in the human gastrointestinal tract, although thought to have its own impact, will also be studied. The microbiome is known to play a crucial role mainly in protecting the host against pathogenic microbes, modulating immunity, regulating metabolic processes, and controlling neuropsychiatric behaviour

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
5
Inclusion Criteria
  • Twins of a heterokaryotypic monozygotic pair discordant for DS
  • Twins of a sex- and class of age-matched dizygotic pair discordant for DS,
  • Sex- and class of age-matched patient with mosaic T21
  • Subject's parents/legal representatives willing to give written informed consent.
  • Subject and his/her parents/legal representatives must be able/willing to comply with the protocol.
  • Subject covered by social welfare.
Exclusion Criteria
  • None

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Down syndrome childrenBiological samplingTwo pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
Primary Outcome Measures
NameTimeMethod
Study of epigenetic modifications1 year

DNA methylation pattern

Identification of active genes1 year

Analysis of transcriptomic profile from RNA samples

Analysis of the coding and non-coding genetic variations between participants1 year

Whole Genome Sequencing of DNA samples

Identification of the proteins regulated differently1 year

Analysis of proteomic profile from plasma samples

Link specific proteins to some specific complications seen in patients with Down syndrome1 year

Analysis of proteomic profile from plasma samples

Determination of the mechanisms of genes regulation1 year

Analysis of transcriptomic profile from RNA samples

Definition of the network of genes expression1 year

Analysis of transcriptomic profile from RNA samples

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institut Jérôme Lejeune

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath